Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations

This study aims to observe the difference between NMAP (nicotinamide metabolism associated protein) serum levels in primary diagnosed renal cancer patients and non-renal cancer patient controls, plot the ROC curve and establish appropriate cut-off values.

Inclusion Criteria: 1. The tumor group patients were found to have renal or hepatic mass, plan to receive surgical treatment (except for radiofrequency ablation, cryoablation, etc., which were not available for pathological examination). The control group patients were ruled out of tumor based on radiological tests and commonly used tumor biomarkers 2. Age ≥ 18 years old and able to provide written informed consent; 3. Have not received any systemic or topical treatment for kidney/liver tumors. 4. Cardiopulmonary, liver and kidney functions are able to tolerate surgery and can comply with research requirements. Exclusion Criteria: 1. The investigators believe that the subject may be unsuitable for inclusion due to severe concurrent diseases, infections, and etc. 2. The subjects is known or suspected of other malignancies. 3. There has been another history of malignancy in the past 5 years. 4. Major surgery (surgery requiring general anesthesia) was performed within 4 weeks prior to screening visits.